Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1CNS 1

Conditions

Ovarian Neoplasms 13Neoplasms 8Breast Neoplasms 7Neoplasm Metastasis 5Prostatic Neoplasms 4Pancreatic Neoplasms 2Glioblastoma 2Fallopian Tube Neoplasms 2Urogenital Neoplasms 1Unilateral Breast Neoplasms 1Triple Negative Breast Neoplasms 1Solid Tumor, Adult 1Solid Tumor 1Sarcoma, Ewing 1Prostatic Diseases 1Prostate Carcinoma Metastatic to the Bone 1Ovarian Diseases 1Osteosarcoma 1Neuroblastoma 1Neoplasm, Residual 1Melanoma 1Lung Neoplasms 1Leukemia, Prolymphocytic, T-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1HER2-negative Metastatic Breast Cancer 1Gonadal Disorders 1Genital Neoplasms, Male 1Genital Neoplasms, Female 1Genital Diseases, Male 1Genital Diseases, Female 1

Interventions

pembrolizumab 92Nivolumab 56Ipilimumab 55Cyclophosphamide 52Vemurafenib 28fludarabine 27aldesleukin 25Interleukin-2 25fludarabine phosphate 21trametinib 20dabrafenib 17Temozolomide 14Biopsy 14Cisplatin 13spartalizumab 12atezolizumab 12Carboplatin 11cobimetinib 10Paclitaxel 10Introns 10CTLA-4 Antigen 10poly ICLC 9binimetinib 9Specimen Handling 9Radiotherapy 9Radiosurgery 9MART-1 Antigen 9tremelimumab 8incomplete Freund's adjuvant 8Radiation 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Melanoma × niraparib × Clear all
NCT01294735 2012-08-15

Study of the Safety and Efficacy of MK-4827 Given With Temozolomide in Participants With Advanced Cancer (MK-4827-014 AM1)

Merck Sharp & Dohme LLC

Phase 1 Completed
19 enrolled
CNSDermatologic

Glioblastoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡